Indeed, p53wild-type melanoma cells responded to the delivered drug with the molecular activation of the p53 pathway and biological events leading to cell cycle block and apoptosis, while p53mutated melanoma cells displayed resistance to the treatments. The gene discussed is TP53; the disease is melanoma.